Incidence of bladder cancer in patients with type 2 diabetes treated with metformin or sulfonylureas

Diabetes Care

Volumn 37, Issue 7, 2014, Pages 1910-1917

  Mamtani, Ronac ^a   Pfanzelter, Nick ^a   Haynes, Kevin ^b   Finkelman, Brian S ^b   Wang, Xingmei ^b   Keefe, Stephen M ^a   Haas, Naomi B ^a   Vaughn, David J ^a   Lewis, James D ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETOHEXAMIDE; CHLORPROPAMIDE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLIQUIDONE; METFORMIN; SULFONYLUREA DERIVATIVE; TOLAZAMIDE; TOLBUTAMIDE; ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER INCIDENCE; CANCER RISK; COHORT ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TREATMENT DURATION; DIABETES MELLITUS, TYPE 2; FACTUAL DATABASE; FOLLOW UP; INCIDENCE; MIDDLE AGED; NEOPLASMS; PATHOLOGY; URINARY BLADDER NEOPLASMS;

AGED; COHORT STUDIES; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; MALE; METFORMIN; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES; SULFONYLUREA COMPOUNDS; URINARY BLADDER NEOPLASMS;

EID: 84903549117     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-1489     Document Type: Article

References (41)

1. Zakikhani M, Dowling RJ, Sonenberg N, Pollak MN. The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res (Phila) 2008;1:369-375
2. Chiong E, Lee IL, Dadbin A, Sabichi AL, Harris L, Urbauer D, et al. Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells. Clin Cancer Res 2011;17:2863-2873.
3. Makhlin I, Zhang J, Long CJ, et al. The mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers. BJU Int 2011;108:E84-E90
4. MilowskyMI, Iyer G, Regazzi AM, et al. Phase II study of everolimus in metastatic urothelial cancer. BJU Int 2013;112:462-470
5. Bodmer M, Meier C, Krähenbühl S, Jick SS, Meier CR. Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 2010;33:1304-1308
6. Bosco JL, Antonsen S, Sorensen HT, Pedersen L, Lash TL. Metformin and incident breast cancer among diabetic women: a population-based case-control study in Denmark. Cancer Epidemiol Biomarkers Prev 2011;20:101-111.
7. Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang YH, Huang YC. Type 2 diabetes increases andmetformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer 2011;11:20
8. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009;52:1766-1777
9. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 2009;32:1620-1625
10. Hassan MM, Curley SA, Li D, et al. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer 2010;116:1938-1946
11. Donadon V, Balbi M, Mas MD, Casarin P, Zanette G. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int 2010;30:750-758.
12. Lai SW, Liao KF, Chen PC, Tsai PY, Hsieh DP, Chen CC. Antidiabetes drugs correlate with decreased risk of lung cancer: a population-based observation in Taiwan. Clin Lung Cancer 2012;13:143-148
13. Bodmer M, Becker C, Meier C, Jick SS, Meier CR. Use of antidiabetic agents and the risk of pancreatic cancer: a case-control analysis. Am J Gastroenterol 2012;107:620-626
14. Wright JL, Stanford JL. Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer Causes Control 2009;20:1617-1622
15. Decensi A, Puntoni M, Goodwin P, et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila) 2010;3:1451-1461
16. Noto H, Goto A, Tsujimoto T, Noda M. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One 2012;7:e33411
17. Tseng CH. Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan. Diabetologia 2011;54:2009-2015
18. Home PD, Kahn SE, Jones NP, Noronha D, Beck-Nielsen H, Viberti G; ADOPT Study Group; RECORD Steering Committee. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia 2010;53:1838-1845
19. Larsson SC, Orsini N, Brismar K, Wolk A. Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia 2006;49:2819-2823 (Pubitemid 44730282)
20. Suissa S, Azoulay L. Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care 2012;35:2665-2673
21. Chisholm J. The Read clinical classification. BMJ 1990;300:1092 (Pubitemid 20158094)
22. Blak BT, Thompson M, Dattani H, Bourke A. Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates. Inform Prim Care 2011;19:251-255
23. Lewis JD, Schinnar R, Bilker WB, Wang X, Strom BL. Validation studies of The Health Improvement Network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf 2007;16:393-401 (Pubitemid 46656860)
24. Haynes K, Forde KA, Schinnar R, Wong P, Strom BL, Lewis JD. Cancer incidence in The Health Improvement Network. Pharmacoepidemiol Drug Saf 2009;18:730-736
25. Mamtani R, Haynes K, Bilker WB, et al. Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study. J Natl Cancer Inst 2012;104:1411-1421
26. Lewis JD, Ferrara A, Peng T, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interimreport of a longitudinal cohort study. Diabetes Care 2011;34:916-922
27. Holman RR. Long-term efficacy of sulfonylureas: a United Kingdom Prospective Diabetes Study perspective. Metabolism 2006;55(Suppl. 1):S2-S5 (Pubitemid 44321897)
28. U.S. Food and Drug Administration. FDA Drug Safety Communication: Update to Ongoing Safety Review of Actos (Pioglitazone) and Increased Risk of Bladder Cancer [article online], 2013. Available from http://www.fda.gov/Drugs/ DrugSafety/ucm259150.htm. Accessed 30 December 2013
29. Mickey RM, Greenland S. The impact of confounder selection criteria on effect estimation. Am J Epidemiol 1989;129:125-137 (Pubitemid 19030705)
30. Rubin D. Multiple Imputation for Nonresponse in Surveys. New York, Wiley, 1987
31. Newton CC, Gapstur SM, Campbell PT, Jacobs EJ. Type 2 diabetes mellitus, insulin-use and risk of bladder cancer in a large cohort study. Int J Cancer 2013;132:2186-2191.
32. Rothwell PM, Price JF, Fowkes FG, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 2012;379:1602-1612
33. Bhaskaran K, Douglas I, Evans S, van Staa T, Smeeth L. Angiotensin receptor blockers and risk of cancer: cohort study among people receiving antihypertensive drugs in UK General Practice Research Database. BMJ 2012;344:e2697
34. Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N Engl J Med 2012;367:1792-1802
35. Suissa S. Immortal time bias in pharmacoepidemiology. Am J Epidemiol 2008;167:492-499 (Pubitemid 351264145)
36. Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC. Association between smoking and risk of bladder cancer among men and women. JAMA 2011;306:737-745
37. Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol 2010;69:4-14
38. Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin D. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalnece Worldwide in 2012. Lyon, France, International Agency for Research on Cancer [article online], 2012. Available from http://globocan.iarc.fr/. Accessed 30 December 2013
39. Miao Jonasson J, Cederholm J, Eliasson B, Zethelius B, Eeg-Olofsson K, Gudbjörnsdottir S. HbA1C and cancer risk in patients with type 2 diabetes - a nationwide population-based prospective cohort study in Sweden. PLoS One 2012;7:e38784
40. Prizment AE, Anderson KE, Yuan JM, Folsom AR. Diabetes and risk of bladder cancer among postmenopausal women in the Iowa Women' s Health Study. Cancer Causes Control 2013;24:603-608
41. Reulen RC, Kellen E, Buntinx F, Brinkman M, Zeegers MP. A meta-analysis on the association between bladder cancer and occupation. Scand J Urol Nephrol Suppl 2008 (218):64-78